The Kensey Nash board of directors unanimously recommended the offer for DSM to acquire all outstanding shares of the company. The agreed price represents a premium of 33 percent to Kensey Nash’s closing share price yesterday.
The acquisition with strengthen DSM’s biomedical business.
More Articles on Orthopedic Devices:
Wright Medical Group Sales Fall 6% After Distributor Transitions
Exactech Hip & Knee Revenue Up, Spine Drops 13%
DJO Global Net Sales Jump 11.7%
